Navigation Links
Drug Company Admits Knowledge Of Side Effects In Monkeys

TeGenero, a German based drug firm that had manufactured TGN-1412, has now admitted that the drug had showed adverse effects//, when tested on monkeys. Four out of the six who were admitted to the intensive care unit of a London based hospital following the drug administration are recovering, according to official reports.

The controversial clinical trial had been conducted at Northwick Park Hospital in Harrow, London. Two of the six volunteers are still under a critical condition. Organ support is being provided to two other study participants. The rest two are off their support systems.

In a pre-clinical trial that involved animals, two monkeys have been reported to develop lymph node inflammation following injection of the experimental drug. The company in response to the above issue has however said that symptoms experienced by the man had no correlation with that documented in monkeys.

'There were adverse effects in a certain dosage. Some of the monkeys developed an increase in the lymph nodes,' said Prof. Johannes Loewer, President, Paul Ehrlich Institute.

The drug company had previously claimed that there had been no drug-related adverse effects. Furthermore, the study participants were told that there had been no instances of adverse effects in the prior tests. The side effect of the drug as seen in monkeys had been high enough to warrant monitoring of the immune system and function in human volunteers.

A previous study conducted in 2002 had warned about the possible risks associated with TGN-1412, much earlier. Human cells subjected to treatment with the drug under experimental conditions were found to suffer a significant level of damage.

Health officials have now questioned how the British authority, could have approved of the human clinical trials of the experimental drug despite the known health hazard. 'We assigned expert assessors to review the original decision in approving the cli nical trial and we found nothing that would question our decision,' said Silke Thomson, spokeswoman, Medicines and Healthcare Products Regulatory Agency, in a response statement.


'"/>




Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Ranbaxy Expands By Acquiring A Generic Company In Belgium
8. Indian Training Company To Train Children In Dubai, Sharjah
9. GE Healthcare to Acquire Swedish Medical Company
10. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
11. New Company Will Seek Drugs Against Diabetes and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the appropriate ... and maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO ... " these requirements are explained. The challenge is to determine how to ...
(Date:3/28/2017)... ... 2017 , ... Neurotechnology , a provider of high-precision ... tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the updated  ... recognition to enable users to check in and out from anywhere via the ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... ... March 28, 2017 , ... A ... achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing ... should be aware of when utilizing dental laboratories and technicians that create these ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
Breaking Medicine Technology: